Zealand Pharma Strengthens Leadership with New Chief Scientific Officer
Zealand Pharma is at a significant crossroads, aiming to enhance its position in the management of obesity and related health issues. To support this ambition, they have announced the appointment of Utpal Singh as Chief Scientific Officer. This strategic move underlines their commitment to advancing innovative peptide therapeutics.
Strategic Vision for Peptide Therapeutics
Appointed during a crucial phase for the company, Utpal Singh will play a pivotal role in leading the discovery and clinical development of peptide medicines. His expertise will enable Zealand Pharma to leverage new technologies, including data and computational science, enhancing their already strong drug discovery efforts.
Expanding the Global Scientific Team
As Chief Scientific Officer, Singh's focus will be on expanding Zealand Pharma's global scientific team. This expansion is crucial for driving the next wave of innovative therapies, which builds upon the company's impressive legacy in drug development. His leadership is expected to catalyze the creation of highly differentiated therapies that follow the company’s track record of successful drug launches.
An Accomplished Background in Pharmaceuticals
Singh joins Zealand Pharma with almost 25 years of rich experience in the pharmaceutical sector, having previously worked as the Senior Vice President of Small Molecule Discovery at Eli Lilly and Company. His tenure at Eli Lilly was marked by significant advancements in their discovery processes, leading to successful clinical candidates across various therapeutic areas.
Commitment to Innovation
In a statement, Adam Steensberg, the Chief Executive Officer of Zealand Pharma, emphasized the strategic importance of Singh’s appointment. He believes that Singh's profound understanding of drug design and development is key to furthering the company’s mission of creating transformative therapies for patients dealing with chronic conditions.
The Future of Obesity Management
Singh expressed excitement about the potential for integrating advancements in data science and machine learning within Zealand Pharma's peptide discovery processes. He believes that these innovations will create a powerful platform for drug discovery, enabling the development of medicines that could significantly impact the management of obesity and other related health issues.
A Strong Academic Foundation
Singh's career in pharmaceuticals began in 2001 at Merck & Co after completing a postdoctoral fellowship in organic chemistry at the Massachusetts Institute of Technology. With a PhD in chemical engineering from The Pennsylvania State University and a BS in the same field from Purdue University, Singh's educational background provides a solid foundation for his new role.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the innovation and development of peptide-based medicines. With over ten drug candidates progressing into clinical development, including two that have successfully reached the market, Zealand Pharma is determined to expand its therapeutic pipeline. Their collaboration with various pharmaceutical companies and strategic partnerships continues to enhance their development capabilities.
Frequently Asked Questions
Who is the new Chief Scientific Officer of Zealand Pharma?
Utpal Singh has been appointed as the new Chief Scientific Officer at Zealand Pharma.
What is Utpal Singh's background in the pharmaceutical industry?
Singh brings nearly 25 years of experience in the pharmaceutical sector, including his role at Eli Lilly, where he led significant advancements in drug discovery.
What are the main objectives of Singh as the Chief Scientific Officer?
His main objectives include leading the discovery of peptide medicines and expanding the global scientific team to drive innovation at Zealand Pharma.
How does Zealand Pharma plan to manage obesity therapeutically?
Through innovative peptide medicines, data science, and machine learning, Zealand Pharma aims to create effective therapies for obesity and related health conditions.
When was Zealand Pharma founded?
Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark.
